|
1
|
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population.
|
Cancer Res
|
2004
|
2.79
|
|
2
|
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
|
Proc Natl Acad Sci U S A
|
2006
|
2.72
|
|
3
|
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.
|
J Natl Cancer Inst
|
2007
|
2.46
|
|
4
|
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.
|
J Neurooncol
|
2009
|
2.33
|
|
5
|
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
|
J Clin Oncol
|
2011
|
1.71
|
|
6
|
Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells.
|
Cancer Res
|
2002
|
1.62
|
|
7
|
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.
|
Cancer Res
|
2007
|
1.60
|
|
8
|
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.
|
Nat Med
|
2012
|
1.52
|
|
9
|
Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.
|
Mol Ther
|
2006
|
1.32
|
|
10
|
Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation.
|
Adv Anat Pathol
|
2002
|
1.29
|
|
11
|
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.
|
Mol Ther
|
2008
|
1.28
|
|
12
|
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
|
Clin Cancer Res
|
2004
|
1.19
|
|
13
|
MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme.
|
Proc Natl Acad Sci U S A
|
2012
|
1.18
|
|
14
|
Extracellular vesicles and their convergence with viral pathways.
|
Adv Virol
|
2012
|
1.18
|
|
15
|
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1.
|
Mol Ther
|
2009
|
1.16
|
|
16
|
Impact of tumor microenvironment on oncolytic viral therapy.
|
Cytokine Growth Factor Rev
|
2010
|
1.13
|
|
17
|
The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.
|
J Virol
|
2012
|
1.13
|
|
18
|
Oncolytic viruses driven by tumor-specific promoters.
|
Curr Cancer Drug Targets
|
2007
|
1.11
|
|
19
|
Pharmacologic and chemical adjuvants in tumor virotherapy.
|
Chem Rev
|
2009
|
1.10
|
|
20
|
Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.
|
Mol Ther
|
2013
|
1.07
|
|
21
|
Directing systemic oncolytic viral delivery to tumors via carrier cells.
|
Cytokine Growth Factor Rev
|
2010
|
1.06
|
|
22
|
Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.
|
Mol Ther
|
2011
|
1.05
|
|
23
|
Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors.
|
Front Biosci
|
2003
|
1.04
|
|
24
|
Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments.
|
Cancer Res
|
2011
|
1.02
|
|
25
|
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
|
Mol Ther
|
2012
|
1.02
|
|
26
|
Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.
|
Cancer Res
|
2012
|
1.01
|
|
27
|
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
|
Cancer Res
|
2014
|
1.00
|
|
28
|
Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations.
|
Cancer Res
|
2013
|
0.99
|
|
29
|
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy.
|
Clin Cancer Res
|
2010
|
0.97
|
|
30
|
Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin.
|
Am J Pathol
|
2010
|
0.97
|
|
31
|
Advances in oncolytic virus therapy for glioma.
|
Recent Pat CNS Drug Discov
|
2009
|
0.94
|
|
32
|
Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
|
Clin Cancer Res
|
2012
|
0.92
|
|
33
|
Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density.
|
J Biol Chem
|
2013
|
0.91
|
|
34
|
Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells.
|
PLoS One
|
2013
|
0.90
|
|
35
|
Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
|
Cancer Res
|
2002
|
0.86
|
|
36
|
Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells.
|
Adv Virol
|
2011
|
0.85
|
|
37
|
Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
|
Neuropathology
|
2012
|
0.84
|
|
38
|
Anti-angiogenic gene therapy in the treatment of malignant gliomas.
|
Neurosci Lett
|
2012
|
0.84
|
|
39
|
VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.
|
Mol Ther
|
2013
|
0.83
|
|
40
|
DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.
|
Clin Cancer Res
|
2013
|
0.82
|
|
41
|
STAT3 activation promotes oncolytic HSV1 replication in glioma cells.
|
PLoS One
|
2013
|
0.81
|
|
42
|
Gene expression profiling of the anti-glioma effect of Cilengitide.
|
Springerplus
|
2013
|
0.81
|
|
43
|
How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?
|
Expert Rev Neurother
|
2013
|
0.78
|
|
44
|
Functional assays for specific targeting and delivery of RNA nanoparticles to brain tumor.
|
Methods Mol Biol
|
2015
|
0.77
|
|
45
|
Gene therapeutics: the future of brain tumor therapy?
|
Expert Rev Anticancer Ther
|
2006
|
0.77
|
|
46
|
Correction: Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity.
|
Dis Model Mech
|
2016
|
0.77
|
|
47
|
Effects of CCN1 and Macrophage Content on Glioma Virotherapy: A Mathematical Model.
|
Bull Math Biol
|
2015
|
0.76
|
|
48
|
How efficient are autophagy inhibitors as treatment for glioblastoma?
|
CNS Oncol
|
2014
|
0.75
|
|
49
|
Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth.
|
Cell Rep
|
2017
|
0.75
|
|
50
|
Oncolytic viruses: extreme treatment for an extreme disease.
|
Future Microbiol
|
2006
|
0.75
|
|
51
|
In vivo brain electrophoresis - a novel method for chemotherapy of CNS diseases.
|
Expert Opin Drug Deliv
|
2015
|
0.75
|